Top Injectable Manufacturer in Mauritius – Reliable Pharmaceutical Solutions
Last Updated: September 9, 2026
TL;DR: Mauritius answers the question we ask of every market — does it name the authorities it will lean on, and is India's CDSCO among them — with a list of the wrong noun. There is no published list of foreign regulatory agencies, but there is a statutory list of PHARMACOPOEIAS, and the Indian Pharmacopoeia is on it by name, in the Pharmacy Act itself. That is recognition of a book of standards, not of an agency, and it opens no fast track. The route that does exist runs through a licensed Mauritian wholesale pharmacy, on certificates that expire every year.
Key Takeaways
The Indian Pharmacopoeia is named in primary legislation. Section 50 of the Finance (Miscellaneous Provisions) Act 2020 amended the definition of "specified standards" in section 2 of the Pharmacy Act 1983, so it now reads British, French, United States, European or Indian Pharmacopoeia, with effect deemed from 1 January 2019. It is not recognition of CDSCO, it creates no abridged or reliance pathway, and it does not waive registration.
The manufacturer keeps the registration, but cannot file alone. The Competition Commission of Mauritius's 2021 market study records that the manufacturer is the applicant and becomes the owner of registration — unusually favourable to an exporter — while having to assign one licensed wholesale pharmacy as its legal technical representative, which carries pharmacovigilance responsibility to the Board. Only licensed Mauritian wholesale pharmacies may import.
Registration is not a purely technical assessment, and it expires annually. The same study reports that alongside quality, safety and efficacy the Board weighs PRICE and the number of comparable products already on the market — an additional generic can be refused because enough similar products exist. A certificate of registration is valid for one year, renewable annually under section 25(6).
Two harder facts, stated not buried. A reported but unpublished criterion looks for licensing in Pharmaceutical Inspection Convention countries for an undefined subset of "highly critical" drugs, and neither Mauritius nor India is a PIC/S Participating Authority. Published fees and timelines conflict across government sources, so we print neither.
Introduction: Why Mauritius Demands a Premium Injectable Manufacturer in Mauritius
Every market in this series opens with the same question: does the country publish a list of foreign regulatory authorities whose decisions it will lean on, and is India's CDSCO among them? Mauritius returns a new answer. It publishes no list of foreign agencies at all — we searched and found none, and found no reliance route keyed to CDSCO or to anyone else. What it publishes instead, in the Pharmacy Act 1983, is a list of a different noun: pharmacopoeias. Since section 50 of the Finance (Miscellaneous Provisions) Act 2020, deemed in force from 1 January 2019, "specified standards" means the British, French, United States, European or Indian Pharmacopoeia.
Read that precisely; over-reading it is the main hazard in this market. A product built to an Indian Pharmacopoeia monograph meets a live statutory quality gate: section 24 prohibits selling a pharmaceutical product that does not conform to specified standards, and section 31(1) applies the same test to Sixth-Schedule therapeutic substances. It does not waive registration under section 25, creates no fast track, and says nothing about GMP or site inspection. A serious injectable manufacturer in Mauritius uses it for what it is — a real advantage on specifications, and nothing more.
What Sets a World-Class Injectable Manufacturer in Mauritius Apart
Factory rules and buyer rules are different rules, and in Mauritius the binding one sits on the buyer. Part VII of the Pharmacy Act licenses factories in Mauritius: "manufacturer" is defined as a person licensed under section 36, and section 36(5) requires adequate facilities for sterile preparations and suitably experienced supervision. A Gujarat plant is not a "manufacturer" within the meaning of that Act. The overseas route is product registration under section 25, made through a licensed wholesale pharmacy established in Mauritius — under section 23 such a wholesaler needs a licence and a full-time pharmacist in charge, and only licensed wholesale pharmacies may import.
What sits above that is unusually good news for an exporter, and easy to get backwards. On the Competition Commission's account, the manufacturer is the applicant and becomes the owner of registration; the Mauritian wholesaler is assigned as legal technical representative and carries pharmacovigilance responsibility to the Board, and authorised distributors are named separately. The Ministry's own published approved-product list corroborates the design: it carries the local representative and the marketing authorisation holder in separate columns, and numerous Indian companies appear as holder. Registration is not owned by the local agent.
Quality Systems Behind Every Injectable Supplied to Mauritius
The registration file is described as being in Common Technical Document format — CTD, and we found no published Mauritius requirement for eCTD or ACTD, so we claim neither. As described in the Competition Commission of Mauritius's 2021 market study, it normally carries the country-of-origin authorisation, the manufacturer's WHO-GMP certification, a Certificate of Analysis and a Certificate of Pharmaceutical Product, full composition with raw-material sourcing, quality and stability data, price information, and two samples. Frame each of those as what the study describes, not as what the Board currently requires: we did not find the Board's guidelines published anywhere, and the Commission reported in 2021 that it was unclear whether they are publicly available at all.
For a sterile injectable the technical work is ordinary aseptic discipline — process simulation for the ISO Class 5 filling line, environmental monitoring, container-closure integrity, sterility and bacterial endotoxin testing by LAL, and validated HPLC and GC methods — carried out knowing that the Board does not systematically submit samples for testing at registration, so the paper file does the work. On stability, we found no published Mauritius-specific climatic-zone designation; the data appear among dossier contents with no stated condition, and exporters should confirm the long-term condition with the Board. Mauritius does not appear on WHO's August 2026 ML3/ML4 list, and CDSCO's own ML3 listing carries the scope "Vaccines (producing)" only.
Looking for a sterile injectable manufacturing partner? Talk to Farbe Firma about your market entry.
Why Farbe Firma is the Trusted Injectable Manufacturer in Mauritius for Global Buyers
Farbe Firma Pvt Ltd is a WHO-GMP certified sterile injectable manufacturer and CDMO based in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries. For Mauritius we build the dossier in CTD structure, supply the WHO-format certificate of a pharmaceutical product and the WHO-GMP certificate, and specify to Indian Pharmacopoeia monographs where that is the appropriate standard — which Mauritius law names directly. Because the file must be lodged through a licensed Mauritian wholesale pharmacy that will also act as legal technical representative, the route begins with a named local partner. We have verified none and recommend none.
Two constraints belong in an honest offer. The first is the market test: registration can be refused on price, or because the Board considers there are already enough similar products with no advantage in price or pharmacological action. The second is the reported PIC criterion — a Mauritian competition-authority study reported that for certain drugs, "in particular, highly critical drugs", the Board looks for licensing in Pharmaceutical Inspection Convention countries. We found no published instrument containing it and its scope is undefined, but it cuts against an Indian-origin file, because India is not a PIC/S Participating Authority. Mauritius is not one either, and appears among the observer countries on ZaZiBoNa's published membership page.
Every figure here carries its basis. The US Commercial Service's Mauritius Country Commercial Guide, published February 2026, puts India at 39% of the market as of 2024 — that figure is unsourced on its page, so we attribute rather than assert it. The Ministry of Health and Wellness states that its pharmaceutical procurement section deals mainly with purchases above MUR 1.2 billion annually, by open international bidding on annual requirements. Population is about 1.24 million on Statistics Mauritius's end-2025 estimate, against 1.27 million on WHO's profile for 2023 on a UN basis. Current health expenditure was 5.6% of GDP in 2023, roughly 45% of it paid out of pocket — which is what makes the price criterion bite.
Explore Farbe Firma: Products | Global Reach | About Us
Frequently Asked Questions (FAQ)
Does Mauritius recognise India's CDSCO?
We found no published list of recognised foreign regulators for Mauritius, and no reliance route keyed to CDSCO. What Mauritius does publish, in the Pharmacy Act itself, is a list of accepted pharmacopoeias — and the Indian Pharmacopoeia is on it, added by section 50 of the Finance (Miscellaneous Provisions) Act 2020 with effect deemed from 1 January 2019. That is recognition of a book of standards, not of an agency's decisions, and creates no abridged pathway. WHO lists CDSCO at maturity level 3 with the scope "Vaccines (producing)" only.
Who registers medicines in Mauritius, and how long does a registration last?
The Pharmacy Board, established under the Pharmacy Act 1983 and sitting under the Ministry of Health and Wellness, advised on applications by the Trade and Therapeutics Committee. Do not confuse it with the Pharmacy Council of Mauritius, which registers pharmacists rather than medicines. Under section 25(6) a certificate of registration is valid for one year from its date and may be renewed annually — not five years, as in most markets.
Can an Indian manufacturer apply to the Pharmacy Board directly?
No. Applications are made through a licensed wholesale pharmacy established in Mauritius, and only such licensed wholesalers may import. The manufacturer is nevertheless the applicant and becomes the owner of the registration, on the Competition Commission's 2021 account; it must assign one wholesale pharmacy as its legal technical representative, which represents it before the Board and carries pharmacovigilance responsibility. The Pharmacy Act's manufacturing-licence regime applies to plants in Mauritius and is not a route for an overseas site.
What does it cost and how long does it take?
We are not going to print either figure, because the published sources conflict. Fees are prescribed by the Pharmaceutical Product (Fees) Regulations 2016, and government sources differ materially. On timelines, published estimates run from about one month to under six months and we could not reconcile them. Confirm both directly with the Board. Beyond registration, each consignment needs a clearance issued by the Registrar through TradeNet, and Sixth-Schedule therapeutic substances — which since 2021 sweep in antibiotics and biological products approved by the Board — need a per-consignment permit.
What can Farbe Firma actually do for a buyer in Mauritius?
Manufacture, and prepare the file. Farbe Firma is a WHO-GMP certified sterile injectable manufacturer and CDMO in Gujarat, India, filling under ISO Class 5 conditions and exporting to more than 30 countries. We build dossiers in CTD and ACTD structure, provide the WHO-format CPP and GMP certificate, and generate stability and aseptic process simulation data. We hold no Mauritian registration and make no claim to one; the route runs through a licensed Mauritian wholesale pharmacy acting as legal technical representative.
Technically Reviewed By: Maulik Sudani | Jignasu Sudani (Technical Expert)
Website: www.farbefirma.org | Email: director@farbefirma.org | Address: Gujarat, INDIA
Request a Quote | View Products | FAQ | Blog
Comments